-
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
•
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like Kinase 4 (PLK4), a critical regulator of centriole duplication, at the 64th American Society of Hematology (ASH) annual meeting. The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202…
-
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
•
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical study for its oral drug candidate APL-1202 in combination with the PD-1 inhibitor tislelizumab as a neoadjuvant therapy for muscular invasive bladder cancer (MIBC). The open-label, multi-center Phase I/II clinical study is designed to evaluate…
-
Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first patient administration of Hexvix (hexyl aminolevulinate hydrochloride) in the Lecheng medical pilot zone in Hainan province. Hexvix is an optical imaging agent used to perform Blue Light Cystoscopy to detect carcinoma of the bladder for…
-
Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment
•
China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I multiple ascending dose (MAD) study (NCT05523141) in healthy subjects for the oral RNA-dependent RNA polymerase (RdRp) inhibitor ASC10 being developed as treatment for COVID-19. The Phase I data demonstrated that all doses of ASC10, including…
-
Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting
•
China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study for CPI-818, a first-in-class ITK inhibitor co-developed by US partner Corvus Pharmaceuticals, at the American Society of Hematology (ASH) 2022 annual meeting. The study has shown the anti-tumor activities in T-cell lymphoma (TCL), alongside therapeutic…
-
JW Therapeutics Presents Carteyva Data at ASH Annual Meeting
•
China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection) in Chinese adults with relapsed/refractory follicular lymphoma (r/r FL) and relapsed/refractory mantle cell lymphoma (r/r MCL) at the 64th American Society of Hematology (ASH) annual meeting. Efficacy and Safety in Relapsed/Refractory Follicular LymphomaIn the pivotal…
-
Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205) at the 64th American Society of Hematology (ASH) annual meeting. Global Multi-Center Phase I/II StudyA global multi-center Phase I/II study for golidocitinib in recurrent refractory peripheral T-cell lymphoma (r/r PTCL) included a total of 51…
-
Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New Drug (IND) filing for its in-house developed selective ATR kinase inhibitor TCC1727 by the US FDA. ATR Kinase and TCC1727 MechanismATR, namely ataxia telangiectasia and Rad-3-related protein, is a family of protein serine/threonine kinases and…
-
Biogen’s Aducanumab Administered to Chinese Patient for First Time
•
US major Biogen’s (NASDAQ: BIIB) Alzheimer’s disease (AD) therapy aducanumab has been administered to a Chinese patient for the first time via the Hainan branch of Ruijin Hospital. The hospital is part of the Boao Lecheng medical pilot zone in Hainan province. Aducanumab: FDA Approval and IndicationAducanumab, a beta amyloid…
-
Stemirna Therapeutics’ COVID-19 mRNA Vaccine Gets EUA in Laos
•
Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use Authorization (EUA) in Laos for its in-house developed COVID-19 mRNA vaccine, used for people aged 18 and above to prevent COVID-19 pneumonia through active immunization. The product, the first home-grown COVID-19 mRNA vaccine approved in…
-
Fujian Cosunter Completes Enrollment for Phase I Study of GST-HG171
•
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced the completion of the enrollment of all subjects and their clinical observation, alongside the clinical study summary report of a Phase I clinical study for its Category 1 GST-HG171. The results showed that GST-HG171 had good safety, tolerability, and pharmacokinetics, which…
-
Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022
•
China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at the San Antonio Breast Cancer Symposium 2022 annual meeting. KN046/Albumin Paclitaxel in Metastatic TNBCThe Phase II clinical trial is designed to evaluate the efficacy, safety, and tolerability of KN046 combined with albumin paclitaxel in the…
-
ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
•
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New Orleans, Louisiana, USA, saw the latest updates from a string of China-based biotechs. Those included CARsgen Therapeutics Holdings Ltd (HKG: 2171), Gracell Biotechnologies Inc (Nasdaq.GRCL), Innovent Biologics Inc., (HKG: 1801), Junshi Biosciences (HKG: 1877, SHA:…
-
RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
•
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained two orphan drug designations (ODD) from the US FDA, for the therapy’s potential use against gastric and pancreatic cancers. RC118: Mechanism and DevelopmentRC118, a novel ADC drug candidate co-developed with contract research organization (CRO) Biocytogen,…
-
Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022
•
China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the 2022 European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO). IBI939 Phase Ib Study ResultsA Phase Ib study to evaluate the safety, tolerability, and efficacy of anti-TIGIT candidate IBI939 in combination with sintilimab in patients with…
-
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
•
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands, and Suzhou (China), announced the conclusion of a Phase I clinical study for its anti-CTLA-4 antibody HBM4003 combined with Junshi Bio’s programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) in advanced melanoma. The study has shown that…
-
Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation
•
The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s (HKG: 1167) KRAS G12C inhibitor JAB-21822 has received breakthrough therapy designation (BTD) status for its potential as a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS p.G12C mutation. The…
-
CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials
•
China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both announced receiving the green light from the National Medical Products Administration (NMPA) to carry out clinical trials for their respective SYH2055 and ASC11, both inhibitor drugs targeting 3-chymotrypsin like protease (3CLpro) for COVID-19. Market Landscape…
-
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
•
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s (HKG: 3692) generic version of Japan firm Takeda Pharmaceutical Co., Ltd’s Firazyr (icatibant) has been approved for marketing in China. Firazyr: Mechanism and Approval HistoryFirazyr, a selective bradykinin B2 receptor antagonist developed by Shire Pharmaceuticals,…
-
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
•
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi Lo (efavirenz, lamivudine, tenofovir) has been approved for marketing in China. The drug was awarded priority review status in May 2020 for use in human immunodeficiency virus type 1 (HIV-1) infection in adults and children…
